Epigral Limited

rs,

oor- 25, P J Tower, Dalal Street, Mumbai 400 001 SYMBOL:- EPIGRAL Scrip Code: 543332 Dear Sirs, Sub.: Investors Presentation on Un-Audited Financial Results – Q1 FY2026 Ref.: Regulation 30 of the

73%

1FY26 - Key Highlights Q1FY26 Operational and Financial Highlights: o Plant utilization stood at 73% vs 76% in previous quarter o YoY Revenue dropped by 6% to ₹ 615 Crore. Revenue contribution from

76%

Key Highlights Q1FY26 Operational and Financial Highlights: o Plant utilization stood at 73% vs 76% in previous quarter o YoY Revenue dropped by 6% to ₹ 615 Crore. Revenue contribution from Derivat

6%

Highlights: o Plant utilization stood at 73% vs 76% in previous quarter o YoY Revenue dropped by 6% to ₹ 615 Crore. Revenue contribution from Derivatives & Specialty business stood at 50% o EBITD

₹ 615 Crore

ghts: o Plant utilization stood at 73% vs 76% in previous quarter o YoY Revenue dropped by 6% to ₹ 615 Crore. Revenue contribution from Derivatives & Specialty business stood at 50% o EBITDA dropped by 7%

50%

dropped by 6% to ₹ 615 Crore. Revenue contribution from Derivatives & Specialty business stood at 50% o EBITDA dropped by 7% to ₹ 163 Crore, however EBITDA margin remained unchanged at 27% on account

7%

re. Revenue contribution from Derivatives & Specialty business stood at 50% o EBITDA dropped by 7% to ₹ 163 Crore, however EBITDA margin remained unchanged at 27% on account of sustained focus on

₹ 163 Crore

venue contribution from Derivatives & Specialty business stood at 50% o EBITDA dropped by 7% to ₹ 163 Crore, however EBITDA margin remained unchanged at 27% on account of sustained focus on efficiency and

27%

stood at 50% o EBITDA dropped by 7% to ₹ 163 Crore, however EBITDA margin remained unchanged at 27% on account of sustained focus on efficiency and product mix o PAT stood at ₹ 160 Cr, however PA

₹ 160

ned unchanged at 27% on account of sustained focus on efficiency and product mix o PAT stood at ₹ 160 Cr, however PAT without deferred tax liability benefit stood at ₹ 79 Cr. o ROCE grew to 24% as on

₹ 79

product mix o PAT stood at ₹ 160 Cr, however PAT without deferred tax liability benefit stood at ₹ 79 Cr. o ROCE grew to 24% as on 30th June 2025 vs 21% as on 30th June 2024 due to improvement in earn

24%

at ₹ 160 Cr, however PAT without deferred tax liability benefit stood at ₹ 79 Cr. o ROCE grew to 24% as on 30th June 2025 vs 21% as on 30th June 2024 due to improvement in earnings o Net Debt/EBITDA

“We expect H2FY26 to be stronger compared to H1FY26.”

“Revenue contribution from Derivatives and Specialty business stood at 50% and we expect this to further increase.”

“Our capex projects of expanding CPVC and Epichlorohydrin capacity are moving as per schedule and are expected to be commissioned within the target timeline and budget.​ We are still left with a land parcel in the current complex for which we will announce a capex to further strengthen our integrated complex.”

“This new chemistry ​p​roject will be on similar lines of our earlier projects, i.e.”

“Responsible Care Certificate 33% 30% 5 Year Revenue CAGR (FY25) 5 Year EBITDA CAGR (FY25) 0.3x 25% Debt to Equity (FY25) ROCE (FY25) Revenue (₹ Crore) 1,555 831 2,196 1,936 2,565”

Capex Highlights

1

Founded

1

Employees

1

Certified

1

Manufacturing facility

1

Integration

1

New Value Chains

1

Capex Highlights

o Capex plans are moving as per schedule and are expected to get commissioned within the timeline and budget o CPVC Resin capacity will reach to 1,50,000 TPA, by adding additional 75,000 TPA o Epichlorohydrin capacity will reach to 1,00,000 TPA, by adding additional 50,000 TPA o Wind Solar Hybrid Power Plant capacity will reach to 38.14 MW, by adding additional 19.80 MW CMD Message “​Q1FY26 quarter ended with slightly lower volume and drop in realizations, however we maintained our EBITDA margin of 27% on account of sustaining efficiency level and better product mix. We expect H2FY26 to be stronger compared to H1FY26. Revenue contribution from Derivatives and Specialty business stood at 50% and we expect this to further increase. Our capex projects of expanding CPVC and Epichlorohydrin capacity are moving as per schedule and are expected to be commissioned within the target timeline and budget.​ We are still left with a land parcel in the current complex for which we will announce a ca

Certified

Responsible Care Certificate 33% 30% 5 Year Revenue CAGR (FY25) 5 Year EBITDA CAGR (FY25) 0.3x 25% Debt to Equity (FY25) ROCE (FY25) Revenue (₹ Crore) 1,555 831 2,196 1,936 2,565

Manufacturing facility

Fully-integrated & automated complex FY21 FY22 FY23 FY24 FY25 # Chlor-Alkali : Caustic Soda - 400 KTPA and Caustic Potash - 21 KTPA Derivatives : CPVC Resin – 75 KTPA, Epichlorohydrin – 50 KTPA, Chloromethanes - 50 KTPA and Hydrogen Peroxide - 60 KTPA Our Journey FY 2007 FY 2010 FY 2015 FY 2017 FY 2020 Epigral Ltd (MFL) incorporated Commissioned 1st Plant Increased capacity to Commissioned • Caustic Potash – • Caustic Soda – 167 21 KTPA • Caustic Soda – 119 KTPA KTPA • CPP – 40 MW • CPP – 60 MW Converted all Membrane to Zero Gap Commissioned • Chloromethanes – 50 KTPA Announced Capex • Epichlorohydrin – 50 KTPA FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 Commissioned • Hydrogen Peroxide – 60 KTPA Increased capacity to • Caustic Soda – 294 KTPA • CPP 96 MW Awarded “Responsible Care” Certificate Listed as an independent entity on 18th August 2021 Announced Capex • Chlorotoluene & Value Chain • Setting up R&D Centre Commissioned • Epichlorohydrin – 50 KTPA • CPVC Resin – 30 KTPA Renamed compa

Integration

o Scale up capacities in existing products o New value added products in existing value chains o Improved market position Opportunities in high growth sectors: o Explore opportunities in various sectors o Increase presence & improve market share o Entering into products which are fully imported

New Value Chains

o Expand chemistry expertise to enter new value chains (specialty chemicals) o Addition of new reaction capabilities Achieving economies of scale: o Optimising existing complex o Achieving efficiency operations to become a low cost producer Historical numbers Financial Performance – P&L Revenue (₹ Crore) EBITDA (₹ Crore and %) PAT (₹ Crore and %) 2,565 32% 33% 2,196 1,936 31% 689 25% 28% 711 1,555 831 509 481 261 16% 16% 12% 10% 353 253 196 14% 357 101 FY2021 FY2022 FY2023 FY2024 FY2025 FY2021 FY2022 FY2023 FY2024 FY2025 FY2021 FY2022 FY2023 FY2024 FY2025 Margin -% Balance Sheet Ratios ROCE (%)# 32% 29% 25% ROE (%) 39% 36% Net Debt/EBITDA (x) 16% 17% 16% 17% 23% 2.1 1.9 2.0 1.3 0.7 FY2021 FY2022 FY2023 FY2024 FY2025 FY2021 FY2022 FY2023 FY2024 FY2025 FY2021 FY2022 FY2023 FY2024 FY2025 #Capital employed in ROCE includes Capital Work in Progress Historic Income Statement Particulars (₹ Cr) FY2021 Total Revenue Gross Profit Gross Margin (%) EBITDA EBITDA Margin (%) Depreciation Finance Co